HCW Biologics Inc. (NASDAQ:HCWB) Sees Significant Increase in Short Interest

HCW Biologics Inc. (NASDAQ:HCWB) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totaling 62,738 shares, an increase of 457.9% from the November 30th total of 11,245 shares. Based on an average trading volume of 50,488 shares, the days-to-cover ratio is currently 1.2 days. Approximately 4.1% of the shares of the company are short sold. Approximately 4.1% of the shares of the company are short sold. Based on an average trading volume of 50,488 shares, the days-to-cover ratio is currently 1.2 days.

Institutional Investors Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Golden State Wealth Management LLC acquired a new stake in HCW Biologics Inc. (NASDAQ:HCWB) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,000 shares of the company’s stock, valued at approximately $40,000. Golden State Wealth Management LLC owned 0.69% of HCW Biologics at the end of the most recent quarter. 2.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $35.00.

HCW Biologics Price Performance

HCW Biologics stock opened at $1.49 on Thursday. The firm has a market capitalization of $4.01 million, a P/E ratio of -0.12 and a beta of 0.66. HCW Biologics has a one year low of $1.42 and a one year high of $41.20. The business has a fifty day moving average price of $2.64 and a 200-day moving average price of $3.81.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings data on Friday, November 14th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.58 by ($3.60). The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $7.00 million.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.